SCHEMBL184178

SCHEMBL184178

CC(C)COC(=O)NC1CCN(c2nc(-c3ccccc3O)nc3ccc(F)cc23)C1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 5/20 0.48
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SMAD3 P84022 1/20 0.39
PDE10A Q9Y233 1/20 0.38
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184179 1.00 CHEK2 (0.48) CHEK2MEN1KMT2ASMAD3PDE10A
Hydrochloric Acid SCHEMBL4991750 0.99 CHEK2 (0.47) CHEK2MEN1KMT2ASMAD3PDE10A
Hydrochloric Acid SCHEMBL4991743 0.99 CHEK2 (0.47) CHEK2MEN1KMT2ASMAD3PDE10A
SCHEMBL14132251 0.91 CHEK2 (0.50) CHEK2MEN1KMT2ASMAD3PDE10A
SCHEMBL184030 0.90 CHEK2 (0.50) CHEK2MEN1KMT2ASMAD3ALDH1A1
SCHEMBL184031 0.90 CHEK2 (0.50) CHEK2MEN1KMT2ASMAD3ALDH1A1
SCHEMBL2603695 0.89 CHEK2 (0.48) CHEK2MEN1KMT2ASMAD3PDE10A
SCHEMBL2603704 0.89 CHEK2 (0.47) CHEK2SMAD3ALDH1A1MAPTTSHR
SCHEMBL12721543 0.88 CHEK2 (0.49) CHEK2MEN1KMT2ASMAD3ALDH1A1
SCHEMBL183869 0.87 CHEK2 (0.46) CHEK2MEN1KMT2ASMAD3PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809353-B2 Quinazolines useful as modulators of voltage gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-19 US disclosed
US-8158637-B2 Sodium channel moderators; antiarrhythmia agents; analgesics; antiarthritic agents; antiinflammatory agents; antieplipetic agents; psychological disorders; nervous system disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-17 US disclosed
EP-1957482-B1 QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS VERTEX PHARMA (US) 2012-01-04 EP disclosed
US-20080221137-A1 Quinazolines useful as modulators of voltage gated ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-09-11 US disclosed
US-20080167305-A1 QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167305-A1 QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS KCNQ1, KCNQ2, KCNQ5 CHEK2 3091/4885MEN1 3006/4885KMT2A 2233/4885
US-20080221137-A1 Quinazolines useful as modulators of voltage gated ion channels KCNQ1, KCNQ2, KCNQ5 CHEK2 3091/4885MEN1 3006/4885KMT2A 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.